News & Media

Main Menu

Press Releases

Amolyt Pharma Announces Research Agreement and Licensing Option with XOMA

January 24, 2023
Download a PDF: EN or FR

Amolyt Pharma Announces $138 Million Series C Financing led by Sofinnova Partners and co-led by Intermediate Capital Group

January 6, 2023
Download a PDF: EN or FR

Amolyt Pharma Announces Positive Safety and Efficacy Results from Second Patient Cohort in its Phase 2a Trial of AZP-3601 for the Treatment of Hypoparathyroidism

October 12, 2022
Download a PDF: EN or FR

Presentations

  • All PRESENTATIONS
  • AZP-3813
  • Eneboparatide (AZP-3601)
All PRESENTATIONS
  • All PRESENTATIONS
  • AZP-3813
  • Eneboparatide (AZP-3601)
Eneboparatide (AZP-3601)

Safety, Tolerability and Pharmacodynamics of AZP-3601, a Novel Long-Acting PTH Analog, in Healthy Adults: Data From a Randomized, Double-Blind, Placebo-Controlled Phase 1 Study. e-ECE 2021.

Written by
jpoly4
Eneboparatide (AZP-3601)

cHP Natural History Study: ISPOR Poster

Written by
jpoly4
Eneboparatide (AZP-3601)

A Single Administration of AZP-3601, a Novel, Long-Acting PTH Analog, Induces a Significant and Sustained Calcemic Response: Preliminary Data From a Randomized, Double-Blind, Placebo-Controlled Phase 1 Study. ENDO 2021.

Written by
jpoly4
Eneboparatide (AZP-3601)

Clinical Burden and Practice Patterns in Patients With Chronic Hypoparathyroidism in the United States (US): A Claims Data Analysis Using Diagnosis Based Criteria. ENDO 2021.

Written by
jpoly4
Eneboparatide (AZP-3601)

Clinical Burden and Practice Patterns in Patients With Chronic Hypoparathyroidism in the United States (US): A Claims Data Analysis Using Surgery Based Criteria. ENDO 2021.

Written by
jpoly4

Upcoming events

Date: June 15-18, 2023 (Chicago, IL)

Date: October 13-16, 2023 (Vancouver, Canada)

Date: November 1, 2023

Social Updates

TWITTER

Scroll to Top